84 related articles for article (PubMed ID: 29503426)
1. [Quantitative Prediction of Drug-Drug Interaction Caused by CYP Inhibition and Induction from In Vivo Data and Its Application in Daily Clinical Practices-Proposal for the Pharmacokinetic Interaction Significance Classification System (PISCS)].
Ohno Y
Yakugaku Zasshi; 2018; 138(3):337-345. PubMed ID: 29503426
[TBL] [Abstract][Full Text] [Related]
2. A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling.
Hisaka A; Kusama M; Ohno Y; Sugiyama Y; Suzuki H
Clin Pharmacokinet; 2009; 48(10):653-66. PubMed ID: 19743887
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information.
Hisaka A; Ohno Y; Yamamoto T; Suzuki H
Pharmacol Ther; 2010 Feb; 125(2):230-48. PubMed ID: 19951720
[TBL] [Abstract][Full Text] [Related]
4. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
5. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment.
Polasek TM; Lin FP; Miners JO; Doogue MP
Br J Clin Pharmacol; 2011 May; 71(5):727-36. PubMed ID: 21223357
[TBL] [Abstract][Full Text] [Related]
6. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
9. Theoretical considerations on quantitative prediction of drug-drug interactions.
Hisaka A; Ohno Y; Yamamoto T; Suzuki H
Drug Metab Pharmacokinet; 2010; 25(1):48-61. PubMed ID: 20208388
[TBL] [Abstract][Full Text] [Related]
10. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
11. Dealing with the complex drug-drug interactions: towards mechanistic models.
Varma MV; Pang KS; Isoherranen N; Zhao P
Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.
Stader F; Kinvig H; Battegay M; Khoo S; Owen A; Siccardi M; Marzolini C
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686151
[TBL] [Abstract][Full Text] [Related]
14. How Informative Are Drug-Drug Interactions of Gene-Drug Interactions?
Lagishetty CV; Deng J; Lesko LJ; Rogers H; Pacanowski M; Schmidt S
J Clin Pharmacol; 2016 Oct; 56(10):1221-31. PubMed ID: 27040602
[TBL] [Abstract][Full Text] [Related]
15. In vitro prediction of clinical drug interactions with CYP3A substrates: we are not there yet.
Greenblatt DJ
Clin Pharmacol Ther; 2014 Feb; 95(2):133-5. PubMed ID: 24448459
[TBL] [Abstract][Full Text] [Related]
16. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
17. Quantitative evaluation of drug-drug interaction potentials by in vivo information- guided prediction approach.
Chen F; Hu ZY; Jia WW; Lu JT; Zhao YS
Curr Drug Metab; 2014; 15(8):761-6. PubMed ID: 25705907
[TBL] [Abstract][Full Text] [Related]
18. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.
Bertz RJ; Granneman GR
Clin Pharmacokinet; 1997 Mar; 32(3):210-58. PubMed ID: 9084960
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.
Waters NJ
Br J Clin Pharmacol; 2015 Jun; 79(6):946-58. PubMed ID: 25443889
[TBL] [Abstract][Full Text] [Related]
20. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
